Skin News and Research

RSS

Vivaglobin therapy effective for patients with primary immunodeficiency

Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.

7 Oct 2010

SMI completes development of SkinSpect for early detection of melanoma

Cascade Technologies Corp. announced today that its wholly-owned subsidiary, Spectral Molecular Imaging, Inc. (SMI), completed, under a previously introduced accelerated timeline, the development of its initial product SkinSpect, aimed at early detection of melanoma by the company's proprietary form of hyperspectral imaging.

7 Oct 2010

Hizentra therapy effective for primary immunodeficiency patients

Hizentra (IgPro20) provides primary immunodeficiency (PI) patients with a safe and effective alternative to other immunoglobulin therapies when given in equivalent doses, according to Phase III pivotal trial data presented today at the XIVth Meeting of the European Society for Immunodeficiencies (ESID).

7 Oct 2010

Vitamin D deficiency may impact orthopaedic procedure outcomes

Forty-three percent of patients scheduled to undergo orthopaedic surgery have insufficient levels of vitamin D and two out of five of those patients had levels low enough to place them at risk for metabolic bone disease, according to a study published this month in the October 6th issue of the Journal of Bone and Joint Surgery (JBJS).

7 Oct 2010

Indoor tanning beds can cause skin cancer

Back to school means new classes, clothes and schedules, including a heavy calendar of social events. Unfortunately, many young adults, particularly young women, head to indoor tanning salons in preparation for high school and college dances in the fall.

7 Oct 2010

'The Pittsburgh Protocol' enables reduction of multiple anti-rejection drugs after transplantation

The Pittsburgh Protocol is unique in utilizing bone marrow cells to enable reduction of the need for multiple anti-rejection drugs after transplantation. The University of Pittsburgh Medical Center is currently the only transplantation center in the world to offer it. An early report of the initial experience with the "Pittsburgh Protocol" in three recipients of upper extremity transplants was presented during the 2010 Annual Clinical Congress of the American College of Surgeons.

7 Oct 2010

Laptop health risks

Doctors warn that balancing the laptop on the knees can cause severe damage to the skin that includes skin discoloration or even cancer.

6 Oct 2010

Michael J. Fox Foundation for Parkinson's Research announces awards totaling $10.1M

The Michael J. Fox Foundation for Parkinson's Research announced awards totaling approximately $10.1 million for five new clinical studies and 14 pre-clinical therapeutic development projects. The funding includes $2.5 million to drive four new clinical trials under the Clinical Intervention Awards, one of the Foundation's Edmond J. Safra Core Programs for PD Research.

6 Oct 2010

Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID

Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.

From Baxter International Inc. 6 Oct 2010

Fisher Wallace Laboratories launches easy-to-use medical device for depression treatment

Fisher Wallace Laboratories today announced the launch of a bold YouTube video campaign that challenges the pharmaceutical drug industry and introduces the company's easy-to-use medical device prescribed for the self-treatment of depression: the Fisher Wallace Cranial Stimulator.

6 Oct 2010

Alma Lasers partners with National Breast Cancer Foundation to combat breast cancer

Alma Lasers, a global developer, manufacturer and provider of laser, light-based, radiofrequency and ultrasound devices for aesthetic and medical applications announced today they will be joining the millions of supporters committed to fighting breast cancer through awareness, education and research.

6 Oct 2010

Isogenica, NovaBiotics to accelerate the development of peptide anti-infective technology

Isogenica Ltd, today announced that it has entered into a collaboration agreement with NovaBiotics, a leading clinical-stage biotechnology company to fast-track the development of NovaBiotic's platform peptide anti-infective technology.

6 Oct 2010

Intervention program prevents smoking relapse, increases breastfeeding duration

New mothers who smoke are less likely to breastfeed. But those who quit smoking during or just prior to becoming pregnant were significantly more likely to remain smoke free and continue breastfeeding if they received support and encouragement during the first eight weeks following child birth, according to a study presented Monday, Oct. 4, at the American Academy of Pediatrics (AAP) National Conference and Exhibition in San Francisco.

5 Oct 2010

Human growth hormone can treat cystic fibrosis symptoms

Human growth hormone can be used successfully to treat some symptoms of cystic fibrosis, but its impact on the disease itself remains unknown, according to a new report funded by HHS' Agency for Healthcare Research and Quality (AHRQ).

5 Oct 2010

NIH to award $64M under Transformative Research Projects program

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.

4 Oct 2010

OHSU CROET issues public alert on Brazilian Blowout hair straightening product

Oregon Health & Science University's Center for Research on Occupational and Environmental Toxicology (CROET) is responding to concerns raised by Portland-area hair salons about a product used for hair straightening. CROET has issued two public alerts describing its findings on the possible negative health impacts of this product.

4 Oct 2010

Californian Hispanics at lower risk of developing melanoma, but develop the disease at younger age

Scientists at the Cancer Prevention Institute of California (CPIC), Stanford University, and the University of Southern California/Keck School of Medicine have found that while Hispanics have much lower risks of developing melanoma than non-Hispanic whites in California, they develop the disease at younger ages, develop thicker tumors, which are more difficult to treat, and experience a higher percentage of cases among people living in poorer neighborhoods.

4 Oct 2010

NIH announces T-R01 project award to examine human microbiome

The National Institutes of Health (NIH) announced today that Martin J. Blaser, MD, the Frederick H. King Professor of Internal Medicine at NYU Langone Medical Center has been awarded one of only twenty NIH Director's Transformative Research Projects (T-R01) award for research entitled "Disappearing Gastrointestinal Microbiota in Epidemic Obesity.

4 Oct 2010

Sculptra dermal filler can make feet feel younger

Most women will sacrifice comfort for fashion, especially when it comes to wearing a gorgeous pair of high heels that make an outfit. Unfortunately, over time, the fat pad at the ball of the foot thins and shifts so bones are not as well padded. Combine these changes with a heel height over two inches and it's a recipe for foot pain. "Now there is an alternative to forsaking your favorite pair of sky high Louboutins, states Dr. Archer.

4 Oct 2010

Suspected hand, foot and mouth disease on Denver flight

Two children arrived on a flight from Mexico to Denver showing symptoms of the contagious illness called ‘hand, foot and mouth’ disease (HFMD) and were checked by paramedics. They were allowed to leave after experts said they were no threat to public health.

4 Oct 2010